List of Therapeutic Companies in Georgia - 30

Accuitis Pharmaceuticals, Inc. is a US registered company with commercial operations located in Atlanta, GA. Accuitis is a participant in the Georgia Research Alliance Venture Lab program and our key technology was discovered by Emory University. We are engaged in the acquisition and development of pharmaceuticals targeting niche, orphan, and underserved disease states. Our lead product is a transformational first in class treatment for Rosacea.

Altesa is a clinical-stage pharmaceutical company dedicated to developing new treatments for age-old threats to human health: high-consequence viral infections. These infections are particularly severe in vulnerable people, including those with chronic health conditions, like lung diseases, as well as the elderly and many people in underserved communities. Altesa builds upon a proven, highly successful drug development platform that has already prevented countless deaths from the two most impactful pandemics of the past 100 years—HIV/AIDS and COVID-19. Our objective is to develop safe and effective antiviral medicines in simple oral dosage forms that, when prescribed for the right people at the right time, will halt the progression of infection before it becomes serious—or even prevent the infection altogether. This strategy extends the proven benefits of testing for viruses such as the flu or COVID-19, which have both caused suffering and death among vulnerable people but can be treated if properly diagnosed. Viral pathogens like these and others have plagued mankind for many thousands of years, but testing for and treating them is an effective strategy to blunt their impact and, ideally, to defeat them.

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company’s lead product candidate is AL001 for the treatment of Alzheimer’s and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient’s immunological system to Alzheimer’s. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

Artelon is the leader in dynamic augmentation of tendon and ligament reconstruction. Specifically designed bio-textiles resiliently reinforce the repair of soft tissue: uniquely restoring native motion, resisting the degradation of reconstruction strength, and supporting tendon and ligament regeneration. Dynamic innovations focused on getting people back to motion faster, stronger, and more stable. Learn more by visiting our website or by subscribing to the Artelon YouTube channel.

Aruna Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body’s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders. We are leveraging our proprietary exosomes and manufacturing platform to create synergistic therapies by enhancing our exosomes with small molecules, RNA, oligonucleotides and antibodies.

BioCircuit Technologies is a medical device company developing tools for the repair of nerve and other tissues.

BioGeometry is an AI-driven biotech dedicated to developing next-generation, programmable protein medicines. We aim to solve the high cost, long lead time, low success rate problems for traditional macromolecular theraputics through the combination of geometric deep learning, structural biology, immunology, and synthetic biology. We enjoy talents from renowned pharmaceutical companies, top-tier AI and bio labs worldwide.

Imagine you need to send a message to a friend. You could mail a letter and they might receive it in a few days. You could drive to their home to tell them the news, dealing with traffic along the way. But, wouldn't it be simpler to just pick up your phone and call or text? It's better. It's faster. At Brain Trust Bio, we are giving life-altering medicines a direct route to the body without the roadblocks and side-effects commonly associated with other drug delivery methods. Now launching Phase I trials in Australia for our revolutionary Intrathecal Drug Delivery Method. The equivalence of these Phase I trials to American standards ensures that findings will be directly accepted in the U.S., allowing for an immediate advancement to Phase II without the need for repetition. Focusing on IT-Riluzole (the only drug demonstrated to prolong survival in ALS), the trials will involve 10 patients over a six-month period and will be conducted by leading medical professionals at Flinders University, Adelaide, and Sunshine Coast Hospital, Birtinya. Brain Trust Bio, an industry leader with a proven track record, which has already shown promising potential. Notably, two patients have been treated for over two years without observed side effects, offering promising indications of the method's ability to extend life expectancy. We are committed to patients because with CNS disorders—like ALS and multiple sclerosis—every second, minute, or hour is more time with loved ones and a step closer to a cure. With ALS—the typical survival rate is two to five years from the time of diagnosis. During that time, those affected lose abilities we often take for granted like walking, talking, and eating independently. They miss important life events like birthdays, anniversaries, or their child's graduation. Brain Trust Bio is making improvements to precision drug delivery and enhancing already available treatments to accelerate positive patient outcomes. Find out more at: www.braintrustbio

Cambium Oncology is a team of scientists, drug development experts, cancer physicians, and business leaders united in a shared vision of treating cancer with a novel immunotherapeutic that targets the VIP signaling pathway. Emory investigators discovered that small molecule antagonists to the VIP receptor on T cells could augment T cell-mediated immune responses to cancer, viral infections, and vaccines. Cambium scientists developed and patented more potent molecules with longer half-lives that induce potent anti-cancer immune responses to leukemia and pancreatic cancer. Cambium Oncology is poised to transform the immuno-oncology field, with a first-in-class therapeutic against a novel immune checkpoint pathway.

Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Dogwood is pioneering Halneuron®, a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain (CINP), cancer pain, and other pain indications. It is also developing the antiviral combination therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID (“LC”) and fibromyalgia (“FM”)

Expression Therapeutics, Inc. is a fully integrated clinical stage gene and cell therapy company developing novel, potentially curative, therapeutics for hematology and oncology. The Company, based in Atlanta, Georgia, has a state-of-the-art 43,000 square foot manufacturing facility in West Chester, Ohio. Expression Therapeutics, Inc. also built a state-of-the-art scalable 43,000 square foot manufacturing facility in Cincinnati, Ohio.

Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.

GeneCure Biotechnologies is a biotechnology company that focuses on developing gene therapy based technologies to treat genetic and acquired human diseases.

GeoVax Labs, Inc., (NASDAQ: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our Modified Vaccinia Ankara - Virus-Like Particle (MVA-VLP) vaccine platform. Our current development programs are focused on vaccines against COVID-19; Hemorrhagic Fever viruses such as Ebola (Zaire, Sudan), Lassa and Marburg; Malaria and Zika virus; and, Human Immunodeficiency Virus (HIV). We have also initiated programs to develop a broadly applicable immunotherapy against tumor associated antigen MUC1 that is expressed of many solid tumor types including breast, ovarian, gastric, liver, pancreas, renal and lymph nodes and immunotherapy to treat human papilloma virus (HPV)-induced cancers.

Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics that modify Parkinson's disease and drive functional reversal inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.

Lanier Biotherapeutics was founded by combining the businesses of Biophtha and Abeome, to further develop an existing first-in-class biologics portfolio for specialty disease, with the ultimate goal of improving the way we survive, age, and live. Lanier targets four major verticals: Multi-functional Retina, Type 2 Inflammation, Dermatology, and ImmunoOncology. Lanier’s lead developments programs include LNR 653.1, a fully humanized anti-VEGF / IL-17A multifunctional antibody for the treatment of retinal neovascularization diseases and LNR 125.36, a fully humanized anti-IL-25 monoclonal antibody for the treatment of Type 2 Inflammatory diseases.

Metaclipse Therapeutics is a preclinical stage biotech company developing novel cancer therapies that are tailored to each patient and their specific tumor. The Company’s first ‘personalized’ cancer therapy is for triple negative metastatic breast cancer. Metaclipse intends to commercialize its products through licensing agreements with major pharmaceutical companies after establishing their safety and effectiveness in early clinical trials by year-end 2019.

Micron Biomedical, Inc. is a clinical-stage biopharmaceutical company on a rapid path to bring to market drugs and vaccines that are formulated into a proprietary patch technology that simplifies and improves the way actives are delivered, stored, and distributed. This technology is designed to increase patient access to drugs and vaccines that would otherwise require expert injection and to improve safety and efficacy by skin targeting.

Moonlight Therapeutics is focused on developing safe, effective, and patient-friendly treatments for people suffering from food allergies. Our first treatment is for children and adults with peanut allergies.

NeuroPn Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases with focus on chronic neuropathic pain and Parkinson’s disease. Developing Non-narcotic, Safe and Innovative Treatments for Neuropathic Pain NeuroPn is addressing the urgent opioid crisis and developing novel, safe, effective, and potentially disease modifying treatments for patients suffering from chronic pain. Developing Novel, Disease Modification Therapies for Parkinson’s Disease NeuroPn is aiming to transform treatments for neurodegenerative diseases and is developing innovative therapies with superior efficacy and improved safety profile over marketed drugs. NeuroPn approach has potential to halt or reverse Parkinson’s disease progression.

NeuroTrauma Sciences (NTS) is a biopharmaceutical company focused on developing therapies to treat the devastating effects of stroke and traumatic brain injury (TBI), including concussion. NTS is taking an innovative approach to the treatment of these conditions by addressing the fundamental underlying biological processes that enable the pathophysiological injury cascade.

Oncorx Pharmaceuticals is an early-stage pharmaceutical company developing high-affinity drugs that selectively target the P-glycoprotein/CD44/Integrin β1 protein complex that is overexpressed on the surface of therapy-resistant tumors. Activation of α5β1 integrin plays an important role in regulating cytoskeletal reorganization, F-actin polarization, the epithelial-to-mesenchymal transition, anchorage-independent tumor cell growth, and tumor cell apoptosis. Currently available cancer therapies are targeted to primary, untransformed tumor cells and are not effective in treating resistant transformed tumors that have entirely different cell surface receptor targets and actin cytoskeletal organization. Oncorx is developing oncology drugs that not only target resistant tumors, but also effectively penetrate the blood-brain-barrier to reach the tumor sanctuary in the brain. Numerous clinical studies have demonstrated that patient survival is strongly dependent upon the time it takes for tumors to reach the brain from their primary site in the body.

Piezo Therapeutics aims to transform the delivery of nucleic acid medicines to enable improved safety, affordability, and scalability. Piezo is developing a uniquely engineered platform that uses electric pulses and microneedles to deliver a broad range of therapeutics inside the body. Its piezoelectric technology offers improved safety and efficacy, and is simple, cost-effective, and rapid to produce at scale. Founded by experts in the field of drug delivery and commercial translation, Piezo's diverse team aims to help translate the next generation of nucleic acid medicines. For more information, please visit www.piezotx.com or email partnerships@piezotx.com.

We are experts in plasma energy with pioneering research in medical plasma technology and a robust patent portfolio. Our company was formed by technology leaders inspired by the potential to transfer the principles of plasma physics and apply these in medicine. From this, a new standard in surgery was born – plasma surgery – and with it, PlasmaJet - the first true plasma surgery system. This important advancement is helping surgeons perform better surgery and maximize clinical benefits for their patients. PlasmaJet has been used to treat more than 45,000 patients in more than 20 countries all over the world. Our Products have proven results and unique value supported by a large clinical database. For more information, please visit www.theplasmajet.com Indications for Use: PlasmaJet System produces plasma energy for dissection, cutting, coagulation and the removal of soft tissue by vaporization in open and videoscopic procedures.

Saol Therapeutics (pronounced "Sail") is a privately held, clinical-stage, pharmaceutical company with operations in Roswell, GA, Dublin, Ireland and Hamilton, Bermuda. The company is focused on development activity in CNS disorders such as pain management and spasticity and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients and the physicians treating these populations and currently has two Phase 2 trials and one Phase 3 trail underway in the United States.

Sebela Pharmaceuticals is a U.S. pharmaceutical company with a market-leading position in Gastroenterology and a focus on innovation in Women’s Health. Our Vision is to build the leading Gastroenterology company in the U.S., with a complementary focus on innovation in Women’s Health, premised on our expertise in pharmaceutical development and commercialization. We value dedication, energy, and enthusiasm, and we focus on innovation and results while striving to achieve our corporate mission and vision. Sebela Pharmaceuticals is committed to cultivating an inclusive environment where all employees are treated with respect. We accomplish this by fostering a culture of diversity, equity and inclusion, which is essential to innovation and continuous improvement. Sebela operates from three locations with offices in Roswell, Georgia, Braintree, MA and headquarters in Dublin, Ireland.

Cancer patients get one chance to save their tumor tissue. Don't throw it away. Unfortunately most tissue is routinely discarded, but SpeciCare aims to change that. Your tumor tissue is as unique as a fingerprint, and holds the key to more effective, precision treatments, leading to improved outcomes, and a better quality of life. We work with cancer patients, and their care team, to uncover treatment options not available without SpeciCare's innovative protocol. Call today to speak to one of our patient advocates. We care about you.

Vernagen aims to discover and develop mRNA based therapeutics using highly advanced mRNA technologies. Our current pipeline includes vaccine platforms targeting various emerging pathogens and biologics platforms aiming to replace current protein based therapeutics. Our mRNA platforms employ multiple innovative chemical and biological components to enhance their therapeutic efficacy and safety.

Vero biotech is an emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions. At Vero Biotech, our mission is to improve the lives of patients by leading the development of innovative technologies for inhaled NO delivery in the acute care hospital setting and beyond, wherever Nitric Oxide treatment is needed. We strive to exceed customer expectations in terms of safety, efficacy, and growth by focusing on the science, development, and commercialization of our innovations.